1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,890 | 5,970 | 16:49 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Devyser Q2 2026 slides: revenue dips on distributor issues, profit holds | 1 | Investing.com | ||
| Mo | Devyser: Umsatz im zweiten Quartal sinkt um 10,7 % wegen Lageranpassung bei Vertriebspartner | 1 | Investing.com Deutsch | ||
| Mo | Devyser Diagnostics Announces Increase In Q2 Bottom Line | 1 | RTTNews | ||
| Mo | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2026 | 455 | GlobeNewswire (Europe) | "As previously announced, the second quarter was weaker than expected. Sales were negatively impacted by a temporary inventory adjustment by our single largest distributor. Underlying demand remains... ► Artikel lesen | |
| 02.07. | Devyser Diagnostics AB: Sales in the second quarter of 2026 weaker than expected | 128 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ) (the "Company" or the "Group") announces that its preliminary sales for the second quarter of 2026 are weaker than indicated by the information and conditions available... ► Artikel lesen | |
| 25.06. | Devyser Diagnostics AB: Devyser secures SEK 8.9M five-year tender and strengthens Italian position | 311 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in Regione Basilicata, Italy, with a total value of SEK 8.9 million. The tender includes several of Devyser's... ► Artikel lesen | |
| 22.05. | Devyser Diagnostics AB: Devyser strengthens its executive management team - Niklas Axelsson appointed new CFO and Sabina Berlin transitions to a new role within the company | 169 | GlobeNewswire (Europe) | Devyser today announces that Sabina Berlin, current CFO, will transition to a new role with responsibility for Investor Relations and Corporate Compliance. At the same time, the company has appointed... ► Artikel lesen | |
| 06.05. | Devyser Diagnostics AB: Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 6 May 2026 | 201 | GlobeNewswire (Europe) | The Annual General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Wednesday, 6 May 2026 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed at the Meeting... ► Artikel lesen | |
| 27.04. | Devyser Diagnostics mit starkem Umsatzwachstum und positivem EBIT im ersten Quartal | - | Investing.com Deutsch | ||
| 27.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2026 | 790 | GlobeNewswire (Europe) | "Devyser is reporting its fourth consecutive quarter with a positive operating result. This is an outcome we are delivering in an external environment that continues to present challenges: headwinds... ► Artikel lesen | |
| 07.04. | Devyser Diagnostics AB: Devyser announces that Chief Commercial Officer will leave the company | 204 | GlobeNewswire (Europe) | Devyser Diagnostics AB today announces that the company's Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.
"During Theis' time... ► Artikel lesen | |
| 01.04. | Devyser Diagnostics AB: Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares | 384 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, announces that the acquisition of all shares in CyberGene AB ("CyberGene") that was announced on 11 February 2026 has today been... ► Artikel lesen | |
| 04.03. | Devyser Diagnostics AB: Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing | 434 | GlobeNewswire (Europe) | Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing (NGS) assay for genetic analysis of thalassemia and sickle cell disease (SCD) available on the European... ► Artikel lesen | |
| 12.02. | Devyser Q4 2025 slides: Revenue growth and positive EBIT mark turnaround year | 1 | Investing.com | ||
| 12.02. | Devyser: Umsatzwachstum und positives EBIT markieren die Trendwende im Geschäftsjahr 2025 | 1 | Investing.com Deutsch | ||
| 12.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2025 | 422 | GlobeNewswire (Europe) | "The fourth quarter confirmed the positive earnings trend that we have seen throughout the year. Operating profit amounted to SEK 18.0 million (-3.7) for the quarter and to SEK 10.1 million (-62.3)... ► Artikel lesen | |
| 11.02. | Devyser Diagnostics AB: Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market | 902 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products | 681 | GlobeNewswire (Europe) | Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related products... ► Artikel lesen | |
| 08.12.25 | Devyser Diagnostics AB: Devyser secures a four-year tender in France for Devyser Compact | 237 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender with Assistance... ► Artikel lesen | |
| 04.12.25 | Devyser Diagnostics AB: Health Canada grants IVD approval to Devyser's NGS-based chimerism test, the first of its kind in Canada | 229 | GlobeNewswire (Europe) | Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With this we... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 71,90 | -0,44 % | Medtronic plc: Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain | Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio-the broadest in the industry.¹
GALWAY, Ireland, July 16, 2026 /PRNewswire/... ► Artikel lesen | |
| HCA HEALTHCARE | 326,50 | -0,24 % | Will Higher Expenses Impact HCA Healthcare's Q2 Earnings? | ||
| LANTHEUS | 93,00 | -1,38 % | Lantheus Holdings, Inc.: Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide) | BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| CAREDX | 33,200 | -2,35 % | Top Biotech Gainers: CareDx Soars On Medicare Policy, ATAI Acquired, Abbott Laboratories Lifts Outlook, APLM On Watch | NORTH CHICAGO (dpa-AFX) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid... ► Artikel lesen | |
| ENVISTA | 23,200 | -2,52 % | Envista Holdings Corporation: Envista Reports First Quarter 2026 Results | BREA, Calif., May 6, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended April 3, 2026.
"We delivered a good start... ► Artikel lesen | |
| GT BIOPHARMA | 0,355 | -0,89 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Third Quarter Fiscal Year 2026 Results | Reports 8.5% Increase in ARR to $22.1 Million, Net Income of $860,000 and 14% Year-over-Year Growth in Adjusted EBITDA
HENDERSON, Nev., May 14, 2026 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026.ISIN NameCA4013392051 GUARDIAN... ► Artikel lesen | |
| CHEMOMETEC | 54,15 | -1,81 % | Chemometec A/S: Growth in revenue and operating profit | Trading statement for Q3 2025/26 (1 January - 31 March 2026) Growth in revenue and operating profit ChemoMetec's revenue was up by 15% in the third quarter of 2025/26 to DKK 142.3 million from DKK... ► Artikel lesen | |
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): INSIDE INFORMATION - (1) DELAY IN PUBLICATION OF THE ANNUAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026 AND FURTHER DELAY IN PUBLICATION ... | ||
| POLAREAN IMAGING | 0,002 | 0,00 % | Polarean: Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 | ||
| FRESENIUS | 43,660 | -0,77 % | Fresenius: Analystenlob sorgt für neuen Schwung - Trading-Tipp des Tages | Die Aktie von Fresenius hat nach einer weitestgehend enttäuschenden ersten Jahreshälfte 2026 ab Juni wieder Fahrt aufgenommen. Nach einem kleinen Rücksetzer sorgen die Analysten der Deutschen Bank für... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,870 | +1,04 % | Dax rutscht tiefer ins Minus - Siemens-Healthineers-Aktien gefragt | Frankfurt/Main - Der Dax hat am Donnerstag bis zum Mittag seine anfänglichen Verluste weiter ausgebaut. Gegen 12:30 Uhr wurde der Leitindex mit rund 24.848 Punkten berechnet, 0,6 Prozent unter dem Schlussniveau... ► Artikel lesen | |
| ZHONGCHAO | 6,255 | +325,51 % | Zhongchao Inc. Announces 1-for-3 Share Consolidation | SHANGHAI, June 25, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,950 | -0,76 % | BERNSTEIN RESEARCH stuft FMC FRESENIUS MEDICAL CARE AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung von Fresenius Medical Care (FMC) mit "Market-Perform" und einem Kursziel von 44,65 Euro gestartet. Mit der Markteinführung... ► Artikel lesen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,97 % bei einem Aktienkurs von 5,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.